Skip to Content
Merck
  • Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT.

Immortalization and characterization of a new canine mammary tumour cell line FR37-CMT.

Veterinary and comparative oncology (2016-05-04)
L R Raposo, C Roma-Rodrigues, P Faísca, M Alves, J Henriques, M C Carvalheiro, M L Corvo, P V Baptista, A J Pombeiro, A R Fernandes
ABSTRACT

Here we describe the establishment of a new canine mammary tumour (CMT) cell line, FR37-CMT that does not show dependence on female hormonal signaling to induce tumour xenografts in NOD-SCID mice. FR37-CMT cell line has a stellate or fusiform shape, displays the ability to reorganize the collagen matrix, expresses vimentin, CD44 and shows the loss of E-cadherin which is considered a fundamental event in epithelial to mesenchymal transition (EMT). The up-regulation of ZEB1, the detection of phosphorylated ERK1/2 and the downregulation of DICER1 and miR-200c are also in accordance with the mesenchymal characteristics of FR37-CMT cell line. FR37-CMT shows a higher resistance to cisplatin (IC50 >50 µM) and to doxorubicin (IC50 >5.3 µM) compared with other CMT cell lines. These results support the use of FR37-CMT as a new CMT model that may assist the understanding of the molecular mechanisms underlying EMT, CMT drug resistance, fostering the development of novel therapies targeting CMT.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Monoclonal Anti-β-Actin antibody produced in mouse, clone AC-15, ascites fluid
Sigma-Aldrich
Anti-Estrogen Receptor-α antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-HER2 antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Monoclonal Anti-CD44 antibody produced in mouse, clone 1E1, purified immunoglobulin, buffered aqueous solution
Sigma-Aldrich
Anti-Vimentin antibody, Mouse monoclonal, clone V9, purified from hybridoma cell culture
Sigma-Aldrich
Anti-EpCAM ICD antibody, Mouse monoclonal, clone 4A7, purified from hybridoma cell culture